Literature DB >> 3258350

The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma.

R J North1, E A Havell.   

Abstract

In agreement with the results of previous studies (1), it was shown that intravenous injection of endotoxin into mice bearing 9-d SA1 sarcoma resulted in a tumor hemorrhagic reaction that rapidly caused necrosis of most of the center of the tumor, and then the complete regression of the rim of living tumor tissue that survived the hemorrhagic reaction. The tumor hemorrhagic reaction was confined to the vascular bed of the tumor, and its rate and extent of development were measured in terms of the intratumor extravasation of 51Cr-labeled syngeneic red cells. The development of the hemorrhagic reaction was associated with the presence in the tumor over a 6-h period of endogenous TNF that was measured in terms of its capacity to kill L929B cells in vitro and identified by its susceptibility to neutralization with a monospecific, polyvalent anti-rTNF antibody. The same antibody was capable in vivo of inhibiting the endotoxin-induced tumor hemorrhagic reaction by only approximately 50%, even when present in the tumor in excess. However, it was capable when given in the same quantity of inhibiting the ability of endotoxin to cause complete tumor regression. The fact that TNF was generated in the tumor during the tumor hemorrhagic reaction, and that infusion of a sufficient quantity of anti-rTNF antibody severely interfered with hemorrhagic necrosis and prevented tumor regression represents convincing evidence that TNF is an essential participant in endotoxin-induced regression of an established SA1 sarcoma. Moreover, because tumor regression, as opposed to hemorrhagic necrosis, failed to occur if the tumor was growing in immunoincompetent mice, but did so if the mice were infused with tumor-sensitized T cells, it can be concluded that an adequate level of T cell-mediated immunity is also an essential requirement for endotoxin-induced tumor regression. The participation of other endotoxin-induced mediators in tumor regression cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258350      PMCID: PMC2188903          DOI: 10.1084/jem.167.3.1086

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  PATTERNS OF INTERFERON APPEARANCE IN MICE INFECTED WITH BACTERIA OR BACTERIAL ENDOTOXIN.

Authors:  W R STINEBRING; J S YOUNGNER
Journal:  Nature       Date:  1964-11-14       Impact factor: 49.962

Review 2.  Interleukin 1: an immunological perspective.

Authors:  S K Durum; J A Schmidt; J J Oppenheim
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

3.  Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse.

Authors:  S Green; A Dobrjansky; M A Chiasson; E Carswell; M K Schwartz; L J Old
Journal:  J Natl Cancer Inst       Date:  1977-11       Impact factor: 13.506

4.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

5.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

6.  The therapeutic significance of concomitant antitumor immunity. II. Passive transfer of concomitant immunity with Ly-1+2- T cells primes established tumors in T cell-deficient recipients for endotoxin-induced regression.

Authors:  R J North
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.

Authors:  E A Havell; W Fiers; R J North
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

8.  The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity.

Authors:  M J Berendt; R J North; D P Kirstein
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

9.  The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity.

Authors:  M J Berendt; R J North; D P Kirstein
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

10.  Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA.

Authors:  I Parr; E Wheeler; P Alexander
Journal:  Br J Cancer       Date:  1973-05       Impact factor: 7.640

View more
  23 in total

1.  Molecular mechanisms in down-regulation of tumor necrosis factor expression.

Authors:  J G Haas; P A Baeuerle; G Riethmüller; H W Ziegler-Heitbrock
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Roles of interleukin-1 and tumor necrosis factor in lipopolysaccharide-induced hypoglycemia.

Authors:  S N Vogel; B E Henricson; R Neta
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

3.  Effect of advanced ageing on the ability of mice to cause tumour regression in response to immunotherapy.

Authors:  P L Dunn; R J North
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

Review 4.  Gold nanoparticles: From nanomedicine to nanosensing.

Authors:  Po C Chen; Sandra C Mwakwari; Adegboyega K Oyelere
Journal:  Nanotechnol Sci Appl       Date:  2008-11-02

5.  Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death.

Authors:  Tsadik Habtetsion; Zhi-Chun Ding; Wenhu Pi; Tao Li; Chunwan Lu; Tingting Chen; Caixia Xi; Helena Spartz; Kebin Liu; Zhonglin Hao; Nahid Mivechi; Yuqing Huo; Bruce R Blazar; David H Munn; Gang Zhou
Journal:  Cell Metab       Date:  2018-06-07       Impact factor: 27.287

6.  Glucocorticoid-mediated inhibition of endotoxin-induced intratumor tumor necrosis factor production and tumor hemorrhagic necrosis and regression.

Authors:  R J North; E A Havell
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

7.  Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I.

Authors:  C L Selinsky; K L Boroughs; W A Halsey; M D Howell
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

8.  Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects.

Authors:  D Yang; M Satoh; H Ueda; S Tsukagoshi; M Yamazaki
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

9.  A phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer.

Authors:  W Fiedler; W Zeller; C J Peimann; H J Weh; D K Hossfeld
Journal:  Klin Wochenschr       Date:  1991-04-04

10.  Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters.

Authors:  Patrycja Koszałka; Ewa Szmit; Andrzej Myśliwski; Jacek Bigda
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-07-23       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.